Comparative Efficacy of Cabozantinib and Ramucirumab After Sorafenib for Patients with Hepatocellular Carcinoma and Alpha-fetoprotein ≥ 400 ng/mL: A Matching-Adjusted Indirect Comparison
mediaposted on 2021-04-02, 12:04 authored by Adis journals on behalf of, Jörg Trojan, Patrick Mollon, Bruno Daniele, Florence Marteau, Lidia Martín, Yuxin Li, Qing Xu, Fabio Piscaglia, Renata Zaucha, Debashis Sarker, Ho Yeong Lim, Marino Venerito
The above graphical plain language summary, videos, infographic and summary slide represent the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2021.
Alpha-fetoprotein (AFP)CabozantinibHepatocellular carcinoma (HCC)Indirect treatment comparison (ITC)Matching-adjusted indirect comparison (MAIC)Monoclonal antibody (mAb)RamucirumabSecond-line (2L)Tyrosine kinase inhibitor (TKI)Vascular endothelial growth factor (VEGF)Plain Language SummaryInterviewAnimationVideo AbstractInfographic